TY - JOUR
T1 - Validation of an improved scale for rating L-DOPA-induced dyskinesia in the mouse and effects of specific dopamine receptor antagonists
AU - Sebastianutto, Irene
AU - Maslava, Natallia
AU - Hopkins, Corey R.
AU - Cenci, M. Angela
N1 - Funding Information:
This study was supported by grants from the Swedish Governmental Funding of Clinical Research (ALF grant 43301 ) and the Swedish Research Council ( VR 521-2011-2994 , to MAC), and from the Michael J. Fox Foundation for Parkinson's Research (Grant ID: 10000 , to CRH).
Publisher Copyright:
© 2016 Elsevier Inc.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Rodent models of L-DOPA-induced dyskinesia (LID) are essential to investigate pathophysiological mechanisms and treatment options. Ratings of abnormal involuntary movements (AIMs) are used to capture both qualitative and quantitative features of dyskinetic behaviors. Thus far, validated rating scales for the mouse have anchored the definition of severity to the time during which AIMs are present. Here we have asked whether the severity of axial, limb, and orolingual AIMs can be objectively assessed with scores based on movement amplitude. Mice sustained 6-OHDA lesions in the medial forebrain bundle and were treated with L-DOPA (3–6 mg/kg/day) until they developed stable AIMs scores. Two independent investigators rated AIM severity using both the validated time-based scale and a novel amplitude scale, evaluating the degree of deviation of dyskinetic body parts relative to their resting position. The amplitude scale yielded a high degree of consistency both within- and between raters. Thus, time-based scores, amplitude scores, and a combination of the two (‘global AIM scores’) were applied to compare antidyskinetic effects produced by amantadine and by the following subtype-specific DA receptor antagonists: SCH23390 (D1/D5), Raclopride (D2/D3), PG01037 (D3), L-745,870 (D4), and VU6004461 (D4). SCH23390 and Raclopride produced similarly robust reductions in both time-based scores and amplitude scores, while PG01037 and L-745,870 had more partial effects. Interestingly, a novel and highly brain penetrable D4 receptor antagonist (VU6004461) markedly attenuated both time-based and amplitude scores without diminishing the general motor stimulant effect of L-DOPA. In summary, our results show that a dyskinesia scale combining a time dimension with an amplitude dimension (‘global AIMs’) is more sensitive than unidimensional scales. Moreover, the antidyskinetic effects produced by two chemically distinct D4 antagonists identify the D4 receptor as a potential future target for the treatment of LID.
AB - Rodent models of L-DOPA-induced dyskinesia (LID) are essential to investigate pathophysiological mechanisms and treatment options. Ratings of abnormal involuntary movements (AIMs) are used to capture both qualitative and quantitative features of dyskinetic behaviors. Thus far, validated rating scales for the mouse have anchored the definition of severity to the time during which AIMs are present. Here we have asked whether the severity of axial, limb, and orolingual AIMs can be objectively assessed with scores based on movement amplitude. Mice sustained 6-OHDA lesions in the medial forebrain bundle and were treated with L-DOPA (3–6 mg/kg/day) until they developed stable AIMs scores. Two independent investigators rated AIM severity using both the validated time-based scale and a novel amplitude scale, evaluating the degree of deviation of dyskinetic body parts relative to their resting position. The amplitude scale yielded a high degree of consistency both within- and between raters. Thus, time-based scores, amplitude scores, and a combination of the two (‘global AIM scores’) were applied to compare antidyskinetic effects produced by amantadine and by the following subtype-specific DA receptor antagonists: SCH23390 (D1/D5), Raclopride (D2/D3), PG01037 (D3), L-745,870 (D4), and VU6004461 (D4). SCH23390 and Raclopride produced similarly robust reductions in both time-based scores and amplitude scores, while PG01037 and L-745,870 had more partial effects. Interestingly, a novel and highly brain penetrable D4 receptor antagonist (VU6004461) markedly attenuated both time-based and amplitude scores without diminishing the general motor stimulant effect of L-DOPA. In summary, our results show that a dyskinesia scale combining a time dimension with an amplitude dimension (‘global AIMs’) is more sensitive than unidimensional scales. Moreover, the antidyskinetic effects produced by two chemically distinct D4 antagonists identify the D4 receptor as a potential future target for the treatment of LID.
KW - Dystonia
KW - Experimental therapeutics
KW - Movement disorders
KW - Parkinson's disease
KW - Rodent models
UR - http://www.scopus.com/inward/record.url?scp=84987956578&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84987956578&partnerID=8YFLogxK
U2 - 10.1016/j.nbd.2016.09.001
DO - 10.1016/j.nbd.2016.09.001
M3 - Article
C2 - 27597526
AN - SCOPUS:84987956578
SN - 0969-9961
VL - 96
SP - 156
EP - 170
JO - Neurobiology of Disease
JF - Neurobiology of Disease
ER -